OncoMed Announces Early Clinical Data for anti-TIGIT Antibody
Phase 1a Dose-Escalation Data Demonstrates a Favorable Safety Profile and Signals of Immune Cell Modulation in Patients with Late Stage […]
Immune Design to Present at Jefferies 2018 London Healthcare Conference
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) — Immune Design (Nasdaq: IMDZ), an immunotherapy company focused […]
Sigma Labs Updates Reporting Dates For Third Quarter 2018 Financial Results and Conference Call
Company to release financial results on Wednesday, November 14, 2016 after market close and host conference call on Friday, November […]
Motorcar Parts of America to Delay Filing of Fiscal Second Quarter 10-Q
LOS ANGELES, Nov. 09, 2018 (GLOBE NEWSWIRE) — Motorcar Parts of America, Inc. (Nasdaq: MPAA) today announced the company will […]
Spring Bank Announces Additional Inarigivir Results at AASLD Conference
*Results from full 24 weeks of dosing from the first three cohorts of the ongoing Phase 2 ACHIEVE trial in […]
Chembio to Participate in Upcoming Investor Conferences
MEDFORD, N.Y., Nov. 09, 2018 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic tests for […]
Study on Molecular Templates’ PD-L1 ETB with Antigen Seeding Technology Presented at SITC Annual Meeting
Antigen Seeding Technology (AST) is a Potent and Complimentary Addition to Company’s Engineered Toxin Bodies (ETB) Technology AUSTIN, Texas, Nov. […]
Liquidia Technologies to Present at Jefferies London Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company […]
Arsanis Reports Financial Results for Third Quarter 2018
WALTHAM, Mass. and VIENNA, Austria, Nov. 09, 2018 (GLOBE NEWSWIRE) — Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused […]
Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade Therapy
Preclinical Data Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting Shows Highly Specific Inhibitor of TGFβ1, SRTβ1-Ab3, […]
